Cagrilintide for appetite suppression: what the trials actually show

What did @p_fonz21 actually say?

The creator gave a personal update on using cagrilintide, which they call "KAG" or "CAG," alongside a GLP-1 medication they refer to as "GOP one." They claim the peptide "helps to stabilize your blood sugar levels, reduce the risk of your insulin resistance, and honestly, it's an appetite suppressant." They also recommend starting at the minimum dose, once weekly, and stress hydration heavily. They make clear they are not a doctor and not giving medical advice.

The framing here is casual and personal, which is actually more honest than a lot of peptide content on TikTok. They are describing their own experience, not prescribing a regimen. They also admit they combine it with a separate GLP-1 agent, using cagrilintide mid-week to bridge appetite suppression between doses. That context matters when evaluating whether the underlying science supports any of this.

Does the science back this up?

Partially, yes. Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. The appetite suppression claim is probably the strongest of the three, and it has legitimate clinical backing. The blood sugar and insulin resistance claims are more complicated.

In the SCALE-NEXT trial (Enebo et al., 2021, The Lancet), cagrilintide as a monotherapy at 2.4 mg weekly produced meaningful weight loss of up to 10.8% over 26 weeks, primarily through reduced caloric intake, which is consistent with appetite suppression. In the CagriSema combination trials, pairing cagrilintide with semaglutide produced weight loss around 15-17% (Frias et al., 2023, The Lancet), with improvements in fasting glucose and HbA1c, which touches on the blood sugar claim.

However, cagrilintide's mechanism is amylin receptor agonism, not direct insulin sensitization. Calling it an insulin resistance reducer is a stretch of the actual pharmacology. The glucose improvements seen in trials are largely secondary to weight loss, not a primary mechanism of the drug itself. That is a meaningful distinction the creator glosses over.

What did they get wrong (or right)?

Credit where it is due: the appetite suppression claim is accurate, and pushing hydration is genuinely good practical advice for anyone on agents that reduce hunger. It is easy to undereat and under-drink when your appetite signals are blunted. The recommendation to start at the lowest dose also reflects what the clinical literature actually supports for tolerability.

What they got wrong is the insulin resistance framing. Saying cagrilintide "reduces the risk of your insulin resistance" implies a direct metabolic mechanism that the research does not currently support as primary. Amylin analogues work largely by slowing gastric emptying, suppressing glucagon secretion, and reducing food intake. Any insulin sensitivity improvements are downstream of weight loss, not a stand-alone drug action. Presenting this as a direct effect overstates the evidence.

The unstated risk here is also worth flagging: using an unregulated compounded peptide mid-week to bridge a GLP-1 dose is a self-constructed stacking protocol with no clinical trial backing. The creator normalizes this without any discussion of unknown interaction risks, which is a gap in the content even if unintentional.

What should you actually know?

Cagrilintide is a real compound with real phase 3 trial data behind it, which separates it from a lot of the peptide content flooding TikTok. It is not approved by the FDA as a standalone drug, and what people are obtaining and injecting outside clinical settings is compounded or research-grade material with no guaranteed purity, dosing accuracy, or safety monitoring.

The combination of cagrilintide and semaglutide, now being developed commercially as "CagriSema" by Novo Nordisk, is showing genuinely impressive results in trials. But those trials use pharmaceutical-grade compounds at verified doses with clinical oversight. Self-administered stacking based on a TikTok schedule is a fundamentally different situation.

If you are interested in agents like this, the conversation belongs with a licensed provider who can evaluate your metabolic health, current medications, and actual clinical eligibility. Using a peptide mid-week to extend appetite suppression between GLP-1 doses sounds logical but has never been studied for safety or efficacy in that context. That is not a reason to dismiss cagrilintide. It is a reason to be honest about what we know and what we are guessing at.